Now these are the kind of moves that needs to happen more often. Whether this will cause a negative impact on the overall market, and the further invention of drugs (including patent control), but the affordability of the medicatoin to an average citizen is a great move.
The typical Chemotherapy can be on an average of 22 times. When summed up with the dosage (somewhere around 250 mg IIRC), the cost comes to approx: (22/4) * 15000 = 82k, which now, will be affordable at 27k.
Mosf of us would be well versed with the Patent system in general. We have patents in every sector - Technology, Agriculture, Pharmacy etc. Most readers in our profession must already be well versed of the Pros/Cons of the Patent system in Software/Technology. Patents in software are more like ammunition. The more you have, the stronger you are. We don't seem much cat fight in Software/Technology because not one organization own all the patents for a product. An IBM ThinkPad might be using a cool track pad feature which might be a patent of Dell. Since the finished product comprises of many patents from different owners in the same industry, it is better to play good with each other. You scratch my back, I scratch yours.
But what about the Pharmaceutical Industry? There, one single patent could comprise the product. I was reading this document from Bruce Lehman which touches upon Patents and Pharmaceutical Industries, but couldn't find an answer to my question.